[HTML][HTML] PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in …
RS Finn, J Dering, D Conklin, O Kalous… - Breast Cancer …, 2009 - Springer
Introduction Alterations in cell cycle regulators have been implicated in human malignancies
including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the …
including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the …
[HTML][HTML] Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
…, C Oliva, SH Stein, LS Williams, J Dering… - Journal of Clinical …, 2008 - ncbi.nlm.nih.gov
Purpose Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1)
and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against …
and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against …
[HTML][HTML] Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell …
RS Finn, J Dering, C Ginther, CA Wilson… - Breast cancer research …, 2007 - Springer
Dasatinib is an orally active small molecule kinase inhibitor of both the src and abl proteins.
To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer …
To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer …
A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer
DJ Cheon, Y Tong, MS Sim, J Dering, D Berel… - Clinical cancer …, 2014 - AACR
Purpose: To elucidate molecular pathways contributing to metastatic cancer progression
and poor clinical outcome in serous ovarian cancer. Experimental Design: Poor survival …
and poor clinical outcome in serous ovarian cancer. Experimental Design: Poor survival …
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer
…, B Winterhoff, KR Kalli, J Dering… - Journal of the …, 2014 - academic.oup.com
Molecular classification of high-grade serous ovarian cancer (HGSOC) using transcriptional
profiling has proven to be complex and difficult to validate across studies. We determined …
profiling has proven to be complex and difficult to validate across studies. We determined …
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
…, T Kolarova, J Qi, K Manivong, J Dering… - Clinical Cancer …, 2011 - AACR
Purpose: PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block
retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the …
retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the …
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
…, A Cassidy, C Haggerty, H Brown, G Ellison, J Dering… - Cancer research, 2010 - AACR
Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of
mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. The range of …
mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. The range of …
Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer
The Notch ligand, JAG1 is associated with breast cancer recurrence. Herein, we report on a
genomics approach to elucidate mechanisms downstream of JAG1 that promote breast …
genomics approach to elucidate mechanisms downstream of JAG1 that promote breast …
[HTML][HTML] Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit …
RS Finn, MF Press, J Dering, M Arbushites… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human
epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast …
epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast …
[HTML][HTML] Mesenchymal gene program–expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance
Metastatic dissemination of ovarian tumors involves the invasion of tumor cell clusters into
the mesothelial cell lining of peritoneal cavity organs; however, the tumor-specific factors that …
the mesothelial cell lining of peritoneal cavity organs; however, the tumor-specific factors that …
